Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elagolix - Abbvie/Neurocrine Biosciences

Next Previous
Drug Profile

Elagolix - Abbvie/Neurocrine Biosciences

Alternative Names: ABT-620; Elagolix sodium; NBI-56418; ORIAHNN; ORILISSA

Latest Information Update: 30 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Analgesics; Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometriosis; Menorrhagia; Pain
  • Phase II Polycystic ovary syndrome; Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 28 Jun 2024 AbbVie completes a phase III trial in Menorrhagia (Combination therapy) in USA and Puerto Rico (PO) (NCT03271489)
  • 04 Jan 2024 No development reported - Phase-III for Endometriosis (Combination therapy) in USA, Puerto Rico, Canada (PO) (Abbvie pipeline January 2024)
  • 04 Jan 2024 No development reported - Phase-III for Endometriosis in Austria, United Kingdom, Italy, Spain, Australia, Czech Republic, New Zealand, South Africa, Hungary, Poland, Argentina, Brazil (PO) (Abbvie pipeline January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top